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Available online 24 April 2015AbstractAim: To assess the role of simple enucleation (SE) for the treatment of highly complex renal tumors.
Methods: Overall, 96 Preoperative Aspects and Dimensions Used for an Anatomical (PADUA) classification score 10 to 13 renal tumors
were treated with SE at our institution. All conventional perioperative variables, surgical, functional and oncological results were gathered
in a prospectively maintained database. Survival curves were generated using a KaplaneMeier method. Univariate analysis assessed the
outcome differences.
Results: Mean (1s.d.) clinical tumor diameter was 4.8 (1.6 cm). 70.8% of patients had cT1b stage. The PADUA score was recorded as
10, 11, 12 and 13 in 57.3%, 29.2%, 11.5%, and 2.1% of tumors respectively. Overall, 76 patients were treated with an open approach and 20
robotically. Mean warm ischemia time (WIT) was 19.2 min, and WIT greater than 25 min occurred in 14.6% of cases. Positive surgical
margin (PSM) rate was 3.6% and trifecta was achieved in 64.3% of patients. Postoperative surgical complications occurred in 24% of pa-
tients, with 14.6% Clavien-Dindo grade 1e2, 8.3% grade 3, and 1% grade 4. Five-year cancer specific survival (CSS), recurrent free sur-
vival (RFS), and overall survival (OS) rates resulted 96.1%, 90.8% and 88.0%, respectively. Overall, 4.2% of patients experienced
progressive disease. At follow-up, the mean decrease of eGFR from preoperative value was 13.9 ml/min. This was not significantly corre-
lated with PADUA score (p ¼ 0.69). The surgical approach was neither a predictor of Trifecta outcome, nor of postoperative complications,
WIT >25 min or PSM rate.
Conclusions: SE is an effective treatment for highly-complex renal tumors, with a potential key role to widen the NSS (nephron sparing
surgery) indications according to guidelines.
 2015 Elsevier Ltd. All rights reserved.
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1Introduction
Surgery remains the mainstay of renal cell carcinoma
(RCC) management. Nephron-sparing surgery (NSS) re-
duces the risk of chronic kidney disease (CKD) development
and may decrease the incidence of postoperative cardiovas-
cular and metabolic sequelae. Onocological outcomesthor. Universita di Firenze, Clinica Urologica I,
Careggi, San Luca Nuovo, 50139 Florence, Italy.
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sevier Ltd. All rights reserved.appear equivalent to radical nephrectomy (RN). However
the adoption of such surgery has been low; especially for
large and highly complex cT1 tumors.2,3 From a surgical
perspective, the complexity of kidney tumors, insufficiently
discriminated by tumor size alone,4 is measured by nephro-
metric scores. The ‘Preoperative Aspects and Dimensions
Used for an Anatomical’ (PADUA) classification is one of
the most widely used.5 To treat challenging cases
(PADUA10 and cT1b), some authors have reported lower
surgical complexity when using simple enucleation
(SE).6e8 SE, either performed as open and robotic approach,9
involves the excision of an RCC without any visible rim of
healthy parenchyma around it. This is achieved by a blunt
935S. Serni et al. / EJSO 41 (2015) 934e940dissection of the natural cleavage plane between tumor
capsule and healthy parenchyma. The efficacy of SE is sup-
ported by studies showing good functional preservation, a
low rate of postoperative CKD, and similar long-term onco-
logical results to those of standard PN.10e12 Nevertheless, no
previous studies have evaluated the results of this technique
in highly complex tumors. The aim of the present study is to
assess perioperative, functional and oncological results of SE
in a series of tumors with PADUA score 10.
Patients and methodsPatient selectionConsecutive patients treated with SE in our department
between July 2006 and August 2013 for clinically localized
RCC were gathered in a prospectively maintained database.
Those with PADUA 10 tumors and were selected for this
study. Both those treated with standard open simple enucle-
ation (OSE) and 20 with Endoscopic Robotic-Assisted Sim-
ple Enucleation (ERASE) were included.9 The approach
selection was based not on the surgical complexity but on
chronological criteria, as ERASE was preferred since
January 2011, with the exception of patients with previous
extensive transperitoneal surgery.Surgical techniqueFor these challenging cases the following technical as-
sessments were used: (1) an accurate study of tumor and
renal vasculature through three-dimensional reconstruction
CT scan (preoperative imaging was readily available for re-
view also during surgery), (2) intraoperative ultrasound
guidance to delineate or confirm the tumor limits of mainly
endophytic tumors.Open simple enucleationOSE was approached by a lombotomic incision, as pre-
viously reported.8 Briefly, the renal pedicle was usually
controlled en bloc with vascular clamps. Renal hypother-
mia was not induced. The natural cleavage plane between
the pseudocapsule and normal parenchyma was developed
by blunt dissection using a peanut, after having incised
the renal capsule few millimeters away from the surface tu-
mor limits. Any tears in UCS or vessels in the enucleation
bed were repaired with running sutures. The parenchymal
defect was closed with horizontal interrupted sutures, after
application of haemostatic agents.Robotic simple enucleationA transperitoneal approach was used for ERASE, with
the patient in a flank position. A miniopen access was
used for a 12 mm periumbilical trocar placement and pneu-
moperitoneum was created. A conventional configurationwith two robotic arms was used, as previously shown.9
Two or three additional trocars for the bed-assistant were
used: one 10e12 mm trocar, one 5 mm trocar and, in
case of right kidney, a subxifoid 5 mm port to retract the
liver. After docking the S/Si DaVinci robot (Intuitive Surgi-
cal, Sunnyvale,USA), the bowel was retracted medially,
Gerota’s fascia was incised and the kidney completely
mobilized. The hilum was identified and renal artery and
vein were isolated. The tumor template was marked with
monopolar cautery. The intracorporeal US guidance (stan-
dard laparoscopic US controlled by the bedside assistant
or a drop-in robotic US probe controlled by the console)
was used to confirm mainly/completely endophytic tumor
burdens. Ischemia was obtained in most of the cases by
bulldog clamp of the main artery. The lesion was blunt
enucleated using Maryland bipolar forceps on the left
hand to push the tumor upward. The monopolar scissors
(closed), controlled by the right hand, alternated the blunt
dissection of the enucleation plane (done with a gentle pres-
sure on the capsulated tumor tissue with the back of the in-
strument) and the coagulation of small parenchymal vessels
(done with the tip). Hemostasis in the resection bed was
achieved with running sutures (Monocryl 2/3-0), according
to the sliding clip technique.13 Care was taken to repair all
visible opened calices and bleeding sites, before placing he-
mostatic agents and closing the cortical defect with sutures.Data collectionAll conventional perioperative (pre-, intra- and postoper-
ative) variables were collected, including nephrometry, warm
ischemic time (WIT), estimated blood loss (EBL), operative
time, length of stay (LOS), medical and surgical complica-
tions (occurring within 30 days of discharge) stratified via
a Clavien-Dindo system.14 Blood loss with need for transfu-
sion, superselective embolization, or re-intervention was
registered. Urinary fistula was recorded in cases of persistent
drainage leakage beyond the seventh postoperative day with
a fluid biochemical analysis consistent with urine (drainage
fluid-to-serum creatinine ratio greater than 2). The change
in laboratory parameters between pre-operative, discharge,
and follow-up were measured, including the estimated
glomerular filtration rate (eGFR) (calculated with Modifica-
tion of Diet in Renal Disease equation15). Surgical specimens
were processed in accordance with standard procedures by
two expert uropathologists. Pathological tumor size, 2009
TNM stage,16 Fuhrman nuclear grade,17 positive surgical
margin (PSM) and histological subtypes according to World
Health Organization classification18 were registered. The
Trifecta rate was calculated as the combination of WIT
<25 min, negative surgical margins, and no complications.19Follow-upThe patients’ status was last evaluated in February 2014.
The follow-up schedule comprised biochemical profiling
Table 1
Perioperative variables of patients with highly complex renal tumors
treated with SE.
Preoperative variables Total
N 96
Age, yrs mean  SD 64  13
Male gender no. (%) 59 (61.4%)
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scan of the abdomen, performed alternately, every 6 months
after surgery for the first 3 years and yearly thereafter. Bone
scintigraphy was performed only in case of clinical suspi-
cion. Patients were assessed periodically after surgery dur-
ing an office visit or by telephone to evaluate their status
and the imaging requested.BMI median (IQR) 24.8 (23.1e27.2)
Charlson index median (IQR) 1 (0e2)
Relative/imperative indication no. (%) 20 (20.8%)Statistical analysis
Patients with preop. CKD stage 3 no. (%) 19 (19.8%)
Preoperative eGFR (ml/min) median (IQR) 79 (64e97)
Clinical diameter (cm) mean  SD (range) 4.8  1.6 (3e10)
PADUA score no. (%)
10 55 (57.3%)
11 28 (29.2%)
12 11 (11.5%)
13 2 (2.1%)
Tumor size score/Clinical stage no. (%)
4 cm 28 (29.2%)
4.1e7 cm 59 (61.5%)
>7 cm 9 (9.3%)
Middle longitudinal location no. (%) 49 (51.0%)
Medial rimno. (%) 40 (41.7%)
50% exophytic tumor no. (%) 11 (11.5%)
<50% exophytic tumor 61 (63.5%)
Completely endophytic tumor 24 (25.0%)
Involved urinary collecting system no. (%) 85 (88.5%)
Involved renal sinusno. (%) 80 (83.3%)
Intraoperative outcomes
Clamping of renal pedicle/artery no. (%) 95/96 (99.0%)
WIT (min) mean  DS (range) 19.2  5.7 (9e38)
WIT > 25 minno. (%) 14 (14.6%)
EBL (cc)mean  DS 196  125
Operative time (min) mean  DS 126  46
Total intraoperative complications no. (%) 3 (3.1%)
➢Transfusions 1 (1.0%)
➢Spleen lesion
(repaired with haemostatic agents)
1 (1.0%)
➢Ureteral lesion (sutured) 1 (1.0%)
Postoperative outcomes
LOS (days, including the day of surgery)
median (IQR)
6 (5e7)
Postoperative overall complicationsno. (%) 25/96 (26.1%)
Postoperative medical complicationsno. (%) 2/96 (2.1%)
Postoperative surgical complicationsno. (%) 23/96 (24.0%)
➢Postop. transfusions (Clavien 2) 12 (12.5%)
➢Selective embolization (Clavien 3a) 5 (5.2%)
➢Reoperation for bleeding (Clavien 3b) 1 (1.0%)
➢Urinary fistula without stenting (Cl.1) 2 (2.1%)
➢Urinary fistula with stenting (Cl.3a) 2 (2.1%)
➢Splenectomy for spleen lesion (Cl. 4) 1 (1.0%)
➢Clavien 5 e
Major (Clavien 3e4) complicationsno. (%) 9 (9.4%)
Delta Hb (3rd postop e Baseline) (g/dL)
mean  DS
2.7  1.3
3rd postop eGFR (g/dL) median (IQR) 68 (51e82)
Pathologic assessment
Benign tumors no. (%) 12/96 (12.5%)
Pathological T stage no. (%)
pT1a 43/84 (51.2%)
pT1b 24/84 (28.6%)
pT3a 17/84 (20.2%)Continuous parametric variables are presented as
mean  standard deviation (SD), nonparametric as median
and interquartile range (IQR), and categorical with fre-
quencies and proportions. The probability of survival was
estimated by KaplaneMeier method. Recurrence-free sur-
vival (RFS) was determined from the day of surgery to
the time of recurrence (local or distant) confirmed by an
imaging technique. Cancer-specific survival (CSS) and
overall survival (OS) were determined from the day of sur-
gery to the death from cancer, or from all cause, respec-
tively, or to last follow-up. Univariate analysis (Pearson’s
chi square, unpaired or paired t test, ManneWhitney U
test) assessed the differences of perioperative variables be-
tween ERASE and OSE, and evaluated the association of
surgical, functional, and oncological results with PADUA
score, stratified according to the median value as 10 vs.
11. An additional univariate analysis appraised the corre-
lation of WIT 25 min and eGFR reduction, in the entire
series and in the subgroup with relative/imperative indica-
tions, analyzed separately. All tests were two-tailed, with
a statistical significance at p < 0.05. All data were analyzed
with the Statistical Package for Social Sciences software,
v.17.0 (SPSS Inc., Chicago,IL,USA).
Results
510 consecutive patients were treated with SE in our
department between July 2006 and August 2013. Of these,
96 had PADUA 10 tumors and were selected for this
study. 76 treated with standard open simple enucleation
(OSE) and 20 with Endoscopic Robotic-Assisted Simple
Enucleation (ERASE).9
Preoperative, surgical and pathologic data of 96 patients
are reported in Table 1. Mean  SD clinical tumor diameter
was 4.8  1.6 cm, and 70.8% of patients had T1b clinical
stage, or higher. Overall, 63.5% were <50% exophytic and
25.0% completely endophytic. The PADUA score was 10,
11, 12 and 13 in 57.3%, 29.2%, 11.5%, and 2.1% of tumors
respectively. Preoperatively, 19.8% of patients had chronic
kidney disease stage 3 or above, and 20.8% were operated
with an imperative/relative indication. Mean WIT and oper-
ative time were 19.2 and 126 min, respectively, with a me-
dian LOS of 6 days. The percentage of patients with
postoperative complications was 24.0%. 2.1% were
Clavien-Dindo stage 1, 12.5% stage 2, 8.3% stage 3, 1%
stage 4). Clavien-dindo stage 3 complications required 5
Table 1 (continued )
Preoperative variables Total
Fuhrman nuclear grade no. (%)
Grade 1e2 65/84 (77.4%)
Grade 3e4 19/84 (22.6%)
Positive surgical margins no. (%) 3/84 (3.6%)
Patients with trifecta no. (%) 54/84 (64.3%)
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bleeding, and 2 ureteral stenting for urinary fistula. We per-
formed a splenectomy for postoperative bleeding following
a splenic injury (Clavien 4 complication). Benign tumors
accounted for 12.5% of patients. Positive surgical margin
(PSM) rate was 3.6% (3/84). The Trifecta outcome was
achieved in 64.3% of patients. At the univariate analysis
no significant difference resulted in ERASE vs. OSE group
regarding all preoperative variables (including the distribu-
tion of nephrometric subscores), with the exception of BMI
which was significantly higher in ERASE group (p ¼ 0.02).
The surgical approach was not a predictor of postoperative
complications, WIT >25 min, PSM rate, and trifecta
outcome.
Functional results are expressed in Table 2 and Fig. 1.
Preoperatively, median (IQR) eGFR was 79 (64e97) ml/
min; eGFR decreased to 68 (51e82)ml/min on the third
postoperative day, and partially recovered to 76 (56e88)
ml/min one month after surgery. At the last point of follow
up mean eGFR was 66 (50e81) ml/min, with a mean
decrease from preoperative value of 13.9  25.0 ml/min af-
ter a mean follow-up of 54 months. Compared to preoper-
ative value, the eGFR reduction at each postoperative visit
was significantly decreased (p < 0.0001). At the last
follow-up visit 29/85 (34%) patients had stage 3e5 CKD,
up 14.2% from baseline. In the entire series,Table 2
Oncological and functional data at latest follow-up.
Follow-up (months) mean  SD (range) 54  26 (15e91)
Patients with available follow-up no. (%) 85/96
Oncological data
Patients with recurrence no. (%) 4/85 (4.7%)
Local recurrence no. (%) 1 (1.2%)
Distant recurrence no. (%) 3 (3.5%)
5yy Recurrence-free survival(%) 90.8%
5yy Cancer-specific survival(%) 96.1%
5yy Overall survival (%) 88.0%
Functional data
Preoperative eGFR (ml/min) median (IQR) 79 (64e97)
Stage 1e2 CKD (eGFR >60) no. (%) 77/96 (80.2%)
Stage 3e4 CKD (eGFR 15e59) no. (%) 19/96 (19.8%)
Stage 5 CKD (eGFR <15) no. (%) 0
Latest eGFR (ml/min) median (IQR) 66 (50e81)
Stage 1e2 CKD (eGFR >60) no. (%) 56/85 (65.9%)
Stage 3e4 CKD (eGFR 15e59) no. (%) 28/85 (33.0%)
Stage 5 CKD (eGFR <15) no. (%) 1 (1%)
Difference in eGFR (preop. e latest) mean (DS) 13.9  25.0
Patients with acquired stage 3e5 CKD at
follow-up, compared to preoperative (%)
þ14.2%WIT25 min did not significantly correlate with eGFR
reduction (p ¼ 0.64), while it significantly correlated with
eGFR reduction in the subgroup with relative/imperative
indications (p ¼ 0.009).
Oncological results are summarized in Table 2 and
Fig. 2. Mean follow-up was 54 (14e96) months. Overall,
11 patients were lost to follow-up and excluded from the
analysis. During this period 7 patients died, two of whom
died of RCC, and 5 of causes independent of RCC. The
mean time to tumor-unrelated death was 41 (21e74)
months. The mean time to cancer-specific death was 30
(17e42) months. The 5-year CSS, RFS, and OS rates re-
sulted 96.1%, 90.8% and 88.0%, respectively. Overall, 4
(4.2%) patients experienced progressive disease. One pa-
tient (1.2%), with a PSM, had local recurrence 50 months
after SE, underwent salvage nephrectomy and was free
from disease at the last follow-up. Three patients experi-
enced distant metastases (3.5%) with no evidence of local
recurrence. Of these, two died 17 and 42 months after sur-
gery, and the third one is alive under therapy with tyrosine
kinase inhibitors.
On univariate analysis, PADUA score 10 versus 11 re-
sulted significantly associated with the achievement of
trifecta and with negative surgical margin, but not with
WIT, complications rate, recurrence rate nor with the
decrease of eGFR from baseline (Table 3).
Discussion
Standard PN is still underused in RCC with adverse
nephrometry, with a frequent recourse to RN also in high-
volume centers. A recent analysis on 1400 patients strati-
fied the treatment choice (PN vs.RN) of 19 surgeons from
3 American centers by tumor complexity, and showed great
variability for intermediate and high complexity tumors.
PN was chosen in 75e100% of low nephrometry tumors,
in 0e100% of intermediate-, and in 0e45% of high-
complexity tumors.2 This variability indicates that many
surgeons are concerned in the short-term by complex re-
constructions, worse surgical outcomes and higher rate of
complications related to high-risk RCC.20 Some authors
suggested a possible advantage of using SE, particularly
when facing tumors with the most unfavourable nephrom-
etry profiles. In this respect SE may reduce the surgical
switch from PN to RN.6e8 Our perioperative results show
that SE has the potentiality to widen the NSS indication
to challenging cases. Indeed, we confirm good surgical re-
sults of SE in highly complex RCC, with a mean WIT of
19.2 min, mean EBL of 200cc, and trifecta achievement
in 64.3% of patients. Postoperative surgical complications
occurred in 24% of patients, but 14.6% were Clavien grade
1e2 as bleeding treated with bedrest and transfusions,
while only 9.4% were major surgical complications. In a
previous study on 65 robotic PN for completely endophytic
RCC, mean WIT, EBL, complications rate and trifecta
achievement resulted 21.7 min, 226cc, 9.2%, and 60%,
Figure 1. Boxplot chart showing estimated glomerular filtration rate (eGFR) modifications according to different evaluations: preoperative, third postoper-
ative day, one month postoperative, and latest follow-up (54  26 months).
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However, in this study only the 35.4% had high-risk nephr-
ometry, and the mean tumor diameter was 2.5 cm.
Other concerns about NSS in highly complex renal tu-
mors may relate to long-term results, as functional recov-
ery. Some authors found that an high nephrometry score
is an independent risk factor for de novo CKD stage 3 or
above after standard PN22 and that tumors classified as
highly complex (R.E.N.A.L.10) were associated with mi-
nor functional volume preservation, and lower percent
eGFR preservation.23 In the present study we show an
eGFR reduction of only 13.9 ml/min from baseline after
a mean of 54 months. We did not found nephrometry score
to significantly predict eGFR decline. These data, taken
together, indicate that SE may give the maximum preserva-
tion of healthy parenchyma possible in highly complex
cases. For the purpose of preservation, SE seems to be
less dependent on nephrometry compared to standard PN.
Our results are strengthened by studies that reaffirmed the
importance of the thickness of healthy parenchyma excisedFigure 2. Recurrence-free survival (RFS), cancer-specific survival (CSS)
and overall survival (OS) estimated with the KaplaneMeier method.along with tumor for the long-term renal function preserva-
tion after NSS.24 Simmons et al. showed that percent kid-
ney volume preservation and not WIT was the primary
determinant of ultimate eGFR after PN, and found that
technical modifications aimed at minimizing healthy vol-
ume loss, while still achieving negative margins, may result
in improved functional outcomes.
A worse oncological outcome has been postulated in
highly complex renal tumors, and in this regard SE might
have a further negative effect. After PN, an high tumor
complexity was associated with higher grade malignancy,25
and with pathological tumor up-staging.26 Few studies on
highly complex RCC are available, and most with short
follow-up, therefore whether the correlation between
adverse pathological findings/poor survival outcome and
higher nephrometry score is stronger than that with higher
TNM stage is still debated. In a study on 80 patients treatedTable 3
Correlation analysis between PADUA and surgical, functional and onco-
logical results.
Result PADUA 10 PADUA 11-13 P
N (%) 55 (57.3%) 41 (42.7%) e
Warm ischemia time
(WIT)mean  SD
18.6  5.7 20.5  5.9 0.12
Postoperative complication
rate no. (%)
13/55 (23.6%) 12/41 (29.3%) 0.88
Clavien-dindo (stage 3e4)
complication rate no. (%)
4/55 (7.3%) 5/41 (12.2%) 0.21
Positive surgical margin
(PSM) no. (%)
1/48 (2.1%) 2/36 (5.5%) 0.047
Patients with trifecta no. (%) 36/48 (75%) 18/36 (50%) 0.035
Tumor recurrence rate no. (%) 2/55 (3.6%) 2/41 (4.9%) 0.85
eGFR (ml/min) reduction: preop.
- last follow-up mean  SD
12  20.3 14.3  30.4 0.69
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high-risk nephrometry was negatively associated with OS,
and provided additional risk assessment beyond clinical T
stage.27 In another study of 19 RPN in RCC with
moderate-high nephrometry score,28 no increased progres-
sion rate was found, but with a median follow-up of 22
months only. In the current study, 5 year RFS and CSS
were 90.8% and 96.1% respectively. The corresponding
survivals in a series of SE with no selection for tumor diam-
eter and complexity were 94.8% and 98.2%, respectively.29
In a series selected for stage (T1b), 5 year CSS after SE was
83.3%.8 These data suggest that SE is oncologically safe in
high-risk tumors, and that the adverse nephrometry may
have a limited pejorative role on the oncological outcomes,
with a lower relevance than tumor stage. Further studies
with larger series and longer follow-up with a specific
aim to compare the prognostic role of the nephrometric
scores with the consolidated prognostic role of the TNM
system are needed to investigate whether a high nephrom-
etry independently affects oncological results of NSS.
SE can be effectively performed both as OSE and
ERASE.9 In the current analysis the surgical approach re-
sulted associated neither with Trifecta nor with its constit-
uents. This suggests that perioperative results of ERASE
are not inferior to OSE also in this clinical settings. How-
ever, comparison between OSE and ERASE was not one
of the aims of the present study and this must be considered
as a preliminary result. Larger series with longer follow-up
of the robotic arm are needed for a reliable comparison of
oncological and functional results.
The limits of this study include its retrospective analysis,
although data were carefully collected in a prospectively
maintained database. We also did not include the
R.E.N.A.L. or the C-Index in the evaluation of adverse
nephrometry. However, to date the PADUA score is the
only nephrometric tool that has been validated for the SE.30
In conclusion, SE is an effective treatment for highly-
complex renal tumors. It has a low rate of major complica-
tions, is oncologically safe, allows a good preservation of
renal function. This may contribute to a widening of the in-
dications for NSS according in future guidelines.
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